Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Multi-Enzyme Supplementation After Mandibular Third Molar Surgery (Trypsin)

12 de novembro de 2026 atualizado por: Özgün Yıldırım, Saglik Bilimleri Universitesi

A Prospective Split-Mouth Evaluation of Multi-Enzyme Supplementation Following Mandibular Third Molar Surgery

This prospective, non-randomized, split-mouth pilot study evaluated the effects of multi-enzyme supplementation on postoperative recovery following bilateral impacted mandibular third molar surgery. Fifteen systemically healthy participants underwent two surgical procedures approximately one month apart. During the first session, the right mandibular third molar was extracted and standard postoperative care was provided. During the second session, the left mandibular third molar was extracted and the same standard care was supplemented with a seven-day course of bromelain, serratiopeptidase, trypsin, chymotrypsin, and nattokinase. Postoperative pain, facial edema, mouth opening, burning sensation, analgesic consumption, bleeding, and wound healing were evaluated during the first postoperative week. Each participant contributed both a control and an intervention surgical site.

Visão geral do estudo

Descrição detalhada

This study was conducted as a prospective, non-randomized, split-mouth pilot investigation involving 15 systemically healthy participants aged 18-45 years with bilateral mesioangular impacted mandibular third molars classified as Pell and Gregory Class II, Position B. Each participant underwent two surgical sessions performed by the same surgeon approximately one month apart.

During the first session, the right mandibular third molar was extracted and participants received standard postoperative medication consisting of amoxicillin/clavulanic acid (875/125 mg) twice daily, paracetamol (500 mg) as needed, and a mouthwash containing 0.12% chlorhexidine gluconate and 0.15% benzydamine hydrochloride three times daily. During the second session, following clinical healing of the first surgical site, the left mandibular third molar was extracted. The same standard postoperative regimen was used, together with a dietary supplement containing bromelain (100 mg), serratiopeptidase (67 mg), trypsin (20 mg), chymotrypsin (10 mg), and nattokinase (60 FU), administered once daily for seven days.

All surgical procedures were performed under local anesthesia using articaine hydrochloride with epinephrine. A full-thickness mucoperiosteal flap was elevated, osteotomy was performed using a surgical chisel under sterile saline irrigation, and the surgical site was closed with 3/0 non-absorbable silk sutures.

Postoperative pain and burning sensation were assessed daily using a 0-10 scale. Analgesic consumption and the presence or absence of bleeding were recorded daily. Facial edema and mouth opening were evaluated through standardized clinical measurements. On postoperative day 7, wound healing was assessed using the Landry Wound Healing Index, ranging from 1 (very poor) to 5 (excellent). Each participant contributed one control and one intervention surgical site, allowing within-participant comparison of postoperative recovery.

Tipo de estudo

Intervencional

Inscrição (Real)

15

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 45 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria

  1. Patients with bilateral impacted mandibular third molars classified as Class II, Position B according to the Pell and Gregory classification and mesioangular according to the Winter classification.
  2. Systemically healthy participants (ASA Class I).
  3. Participants aged 18-45 years.
  4. Willingness to participate and provision of informed consent.

Exclusion Criteria

  1. Age outside the specified range.
  2. Pregnancy or breastfeeding.
  3. Acute pericoronitis or signs of infection associated with the impacted third molar.
  4. Cystic or tumor-like lesions in the surgical region.
  5. History of allergies.
  6. Presence of systemic disease.
  7. Unwillingness to participate.
  8. Poor oral hygiene that may adversely affect wound healing.
  9. Tobacco or alcohol dependence.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Control Group

During the first surgical session, the right impacted mandibular third molar was extracted. Participants received standard postoperative care consisting of amoxicillin/clavulanic acid (875/125 mg) twice daily, paracetamol (500 mg) as needed, and a mouthwash containing 0.12% chlorhexidine gluconate and 0.15% benzydamine hydrochloride three times daily. No multi-enzyme supplement was administered.

Pain will be assessed using a VAS on the 1st, 2nd, 3rd, and 7th postoperative days. For this purpose, the patient will be shown a 100-mm line with "0" at the left end and "100" at the right end. They will be instructed to mark the point on this line where their pain corresponds. The distance from the marked point to "0" will be measured with a ruler, and the resulting value will be recorded in mm to obtain the VAS score. Changes in these measurements will be recorded.

In addition, the number of analgesics required by the patients up to the 7th postoperative day will be recorded.

To assess edema, the tragus, lateral cauntus, corner of the mouth, and soft tissue pogonion points on the patient's face were marked preoperatively. Preoperatively, on the first, second, third, and seventh postoperative day, measurements will be taken and recorded between the Gonion-corner of the mouth, the Tragus-corner of the mouth, and the Gonion-lateral cauntus points.

To assess trismus, the distance between the incisal edges of the upper and lower incisors will be measured and recorded with the mouth maximally open, preoperatively, and on the first, second, third, and seventh postoperative day.

Experimental: Multi-Enzyme Supplementation Group

During the second surgical session, approximately one month after the first operation and following clinical healing, the left impacted mandibular third molar was extracted. Participants received the same standard postoperative care as in the control session, with the addition of a multi-enzyme dietary supplement containing bromelain (100 mg), serratiopeptidase (67 mg), trypsin (20 mg), chymotrypsin (10 mg), and nattokinase (60 FU), administered once daily for seven postoperative days.

Pain will be assessed using a VAS on the 1st, 2nd, 3rd, and 7th postoperative days. For this purpose, the patient will be shown a 100-mm line with "0" at the left end and "100" at the right end. They will be instructed to mark the point on this line where their pain corresponds. The distance from the marked point to "0" will be measured with a ruler, and the resulting value will be recorded in mm to obtain the VAS score. Changes in these measurements will be recorded.

In addition, the number of analgesics required by the patients up to the 7th postoperative day will be recorded.

To assess edema, the tragus, lateral cauntus, corner of the mouth, and soft tissue pogonion points on the patient's face were marked preoperatively. Preoperatively, on the first, second, third, and seventh postoperative day, measurements will be taken and recorded between the Gonion-corner of the mouth, the Tragus-corner of the mouth, and the Gonion-lateral cauntus points.

To assess trismus, the distance between the incisal edges of the upper and lower incisors will be measured and recorded with the mouth maximally open, preoperatively, and on the first, second, third, and seventh postoperative day.

A dietary supplement containing bromelain (100 mg), serratiopeptidase (67 mg), trypsin (20 mg), chymotrypsin (10 mg), and nattokinase (60 FU), administered orally once daily for seven days after mandibular third molar surgery, in addition to standard postoperative care.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Wound healing
Prazo: Postoperative day 7

Wound healing was assessed on postoperative day 7 using the Landry Wound Healing Index. The index ranges from 1 (very poor healing) to 5 (excellent healing), based on tissue color, bleeding on palpation, granulation tissue, incision margins, and suppuration.

Postoperative day 7
Postoperative pain
Prazo: Postoperative days 1-7

Postoperative pain intensity was recorded daily for seven days using a 0-10 visual analog scale, where 0 indicates no pain and 10 indicates the worst imaginable pain. Changes in pain scores over time were evaluated.

Postoperative days 1-7
Postoperative Burning Sensation
Prazo: Postoperative days 1-7

Burning sensation intensity was recorded daily for seven days using a 0-10 scale, where 0 indicates no burning sensation and 10 indicates the most severe imaginable burning sensation.

Postoperative days 1-7
Facial Edema
Prazo: Preoperative assessment and postoperative days 1, 2 and 7

Facial edema was assessed using standardized linear facial measurements between predefined anatomical landmarks. Measurements were obtained preoperatively and on postoperative days 1, 2 and 7. Changes in these measurements over time were evaluated.

Preoperative assessment and postoperative days 1, 2 and 7
Mouth Opening (Trismus)
Prazo: Preoperative assessment and postoperative days 1, 2 and 7

Maximum mouth opening was measured in millimeters as the interincisal distance between the upper and lower incisors. Changes in mouth opening were evaluated over the postoperative follow-up period.

Preoperative assessment and postoperative days 1, 2 and 7
Postoperative Bleeding
Prazo: Postoperative days 1-7

Participants recorded the presence or absence of postoperative bleeding daily for seven days. Bleeding was evaluated as a binary outcome (yes/no), and changes in bleeding probability over time were analyzed.

Postoperative days 1-7
Postoperative Analgesic Consumption
Prazo: Postoperative days 1-7

Participants recorded the number of analgesic tablets consumed daily during the first seven postoperative days. Daily analgesic consumption was compared between the control and intervention surgical sessions.

Postoperative days 1-7

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of analgesic tablets consumed postoperatively
Prazo: From postoperative day 1 to day 7

Participants will record the number of analgesic tablets taken each day for 7 days after surgery in a home diary. The total number of tablets consumed will be calculated. Unit of Measure: Number of tablets per patient

From postoperative day 1 to day 7

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de dezembro de 2025

Conclusão Primária (Real)

28 de abril de 2026

Conclusão do estudo (Real)

10 de setembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

25 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

25 de novembro de 2025

Primeira postagem (Real)

8 de dezembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 15.05.2025-2025/9-9/11

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Patient information will be kept confidential.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever